Exelixis Announces Data From Zanzalintinib+Atezolizumab Study, Stock Drops In Pre-Market

Exelixis, Inc. (EXEL), Monday announced data from STELLAR-303, evaluating zanzalintinib in combination with atezolizumab versus regorafenib for patients with metastatic colorectal cancer.The combination therapy improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20 percent in the intention-to-treat population.The 12- and 24- month survival rate was 46 percent and 20 percent, respectively, for those receiving the combination ther ...